Tolebrutinib Synthesis With Crystallization-Based Purity Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for synthesizing tolebrutinib (Compound (I)) are inefficient, leading to high waste and impurity levels, and are not suitable for large-scale manufacturing due to the use of undesirable solvents and low yield.
Innovation Solution
A method involving the reaction of Formula (A-oxalate hydrate) with 3-chloropropanoic acid and 1,8-diazabicyclo[5.4.0]undec-7-ene in the presence of specific solvents and conditions to produce tolebrutinib (Formula (I)), with controlled temperature and solvent exchange to minimize impurities and improve yield.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If column chromatography purification is used to purify crude Compound (1), then product purity is improved, but yield is significantly reduced (loss of nearly 50%)
Solution Approach 1:
The patent extracts and removes the problematic purification step (column chromatography) from the synthesis process. Instead of using column chromatography, the invention employs a crystallization-based purification method that achieves high purity without the 50% yield loss associated with chromatographic separation.
Solution Approach 2:
The patent changes the purification parameter from chromatographic separation to crystallization-based separation. By adjusting solvent composition and temperature parameters during crystallization, the method achieves both high purity and high yield, resolving the contradiction between these two parameters.
2Ease of manufacture
If a 10-step synthesis method involving multiple solvents is used, then complete chemical transformation is achieved, but waste generation increases and environmental impact worsens
Solution Approach 1:
The patent extracts and removes unnecessary solvent steps from the 10-step synthesis method. By eliminating redundant solvent exchanges and purification steps, the method reduces waste generation while maintaining complete chemical transformation through the essential reaction steps.
Solution Approach 2:
The patent implements continuous reaction and crystallization processes that maintain useful chemical action throughout the synthesis. By avoiding interruptions and redundant purification steps, the method reduces waste while ensuring complete transformation of starting materials to product.
3Manufacturing precision
If bench-scale synthesis methods are used, then product purity can be achieved, but scalability to large-scale manufacturing is limited
Solution Approach 1:
The patent changes the purification parameter from chromatography to crystallization, which is inherently more scalable. Crystallization processes can be easily scaled from bench to industrial scale by adjusting parameters like solvent volume, temperature, and addition rate, while maintaining the same high purity product.
Solution Approach 2:
The patent creates a universal synthesis method that functions effectively at both bench scale and large scale. The crystallization-based purification approach serves multiple functions: it purifies the product, concentrates it, and enables scalable manufacturing, making the method universally applicable across different production scales.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method achieves a high-purity tolebrutinib product with reduced impurities, meeting commercial production requirements and minimizing environmental impact.
Implementation Method 1
reacting a compound of Formula (A-oxalate hydrate) to form the compound of Formula (I)
Implementation Method 2
controlled temperature and solvent exchange to minimize impurities and improve yield
Data Source
AI summary
Disclosed herein are improved synthetic routes for making (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-phenoxyphenyl)-1H-imidazo[4,5-c]pyridin-2(3H)-one (tolebrutinib). Also disclosed herein are novel compounds used in the synthesis of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-phenoxyphenyl)-1H-imidazo[4,5-c]pyridin-2(3H)-one.